Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 576

1.

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S.

J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.

PMID:
22508812
[PubMed - indexed for MEDLINE]
2.

Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Oncol Rep. 2010 May;23(5):1213-20.

PMID:
20372832
[PubMed - indexed for MEDLINE]
3.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

PMID:
21788566
[PubMed - indexed for MEDLINE]
4.

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.

Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.

Cancer. 2010 Mar 15;116(6):1431-9. doi: 10.1002/cncr.24876. Erratum in: Cancer. 2011 May 15;117(10):2238.

PMID:
20131351
[PubMed - indexed for MEDLINE]
Free Article
5.

Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.

Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R.

Oncology. 2011;80(5-6):341-9. doi: 10.1159/000330203. Epub 2011 Jul 26.

PMID:
21791944
[PubMed - indexed for MEDLINE]
6.

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.

Natoli C, Vici P, Sperduti I, Grassadonia A, Bisagni G, Tinari N, Michelotti A, Zampa G, Gori S, Moscetti L, De Tursi M, Panebianco M, Mauri M, Ferrarini I, Pizzuti L, Ficorella C, Samaritani R, Mentuccia L, Iacobelli S, Gamucci T.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1229-40. doi: 10.1007/s00432-013-1436-y. Epub 2013 Apr 20.

PMID:
23604446
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J.

Invest New Drugs. 2012 Feb;30(1):408-16. doi: 10.1007/s10637-010-9555-7. Epub 2010 Oct 5.

PMID:
20922557
[PubMed - indexed for MEDLINE]
8.

Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.

Matsubara N, Mukai H, Fujii S, Wada N.

Breast Cancer Res Treat. 2013 Jan;137(1):203-12. doi: 10.1007/s10549-012-2344-6. Epub 2012 Nov 27.

PMID:
23184081
[PubMed - indexed for MEDLINE]
9.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

PMID:
17438091
[PubMed - indexed for MEDLINE]
Free Article
10.

HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Yao L, Liu Y, Li Z, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.

Ann Oncol. 2011 Jun;22(6):1326-31. doi: 10.1093/annonc/mdq612. Epub 2010 Dec 31.

PMID:
21196440
[PubMed - indexed for MEDLINE]
Free Article
11.

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.

J Clin Oncol. 2011 Jun 1;29(16):2150-7. doi: 10.1200/JCO.2010.31.9079. Epub 2011 Apr 25.

PMID:
21519019
[PubMed - indexed for MEDLINE]
12.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Epub .

PMID:
19758440
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
[PubMed - indexed for MEDLINE]
14.

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Natl Cancer Inst. 2012 Mar 7;104(5):406-14. doi: 10.1093/jnci/djr543. Epub 2012 Jan 16.

PMID:
22250182
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

PMID:
21917518
[PubMed - indexed for MEDLINE]
Free Article
16.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

PMID:
23098527
[PubMed - indexed for MEDLINE]
Free Article
17.

Prognostic significance of molecular classification of breast invasive ductal carcinoma.

Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.

Arch Gynecol Obstet. 2009 Jul;280(1):43-8. doi: 10.1007/s00404-008-0867-1. Epub 2008 Dec 11.

PMID:
19082617
[PubMed - indexed for MEDLINE]
18.

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.

Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF.

Ann Oncol. 2013 Dec;24(12):2990-4. doi: 10.1093/annonc/mdt364. Epub 2013 Sep 7.

PMID:
24013581
[PubMed - indexed for MEDLINE]
19.

Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.

von Minckwitz G, Loibl S, Maisch A, Untch M.

Breast. 2011 Oct;20 Suppl 3:S142-5. doi: 10.1016/S0960-9776(11)70312-5. Review.

PMID:
22015282
[PubMed - indexed for MEDLINE]
20.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators.

J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27.

PMID:
18505968
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk